PARP1 and breast carcinoma: TN breast cancer patients without BRCA mutations largely did not respond to olaparib monotherapy in a phase 2 trial,22 whereas preclinical studies and phase 1 trials suggested that PARP inhibitors can be efficacious in these patients when combined with DNA damaging cytotoxic agents.17